Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kanta Subbarao

Showing results (281-290 of 300) with videos related to

Pageof 30
Sort By:
Communications Medicine|May 23, 2022
A case report describing the immune response of an infant with congenital heart disease and severe COVID-19Danielle Wurzel, Melanie R Neeland, Jeremy Anderson, et al.
Nature Communications|November 12, 2020
Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19Shidan Tosif, Melanie R Neeland, Philip Sutton, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 24, 2021
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect micePhillip Pymm, Amy Adair, Li-Jin Chan, et al.
BMJ Open|October 29, 2021
BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial)Laure F Pittet, Nicole L Messina, Kaya Gardiner, et al.
NPJ Vaccines|October 6, 2025
Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccinationRuth A Purcell, Marios Koutsakos, Lukasz Kedzierski, et al.
Cell Reports|October 5, 2021
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domainAdam K Wheatley, Phillip Pymm, Robyn Esterbauer, et al.
Ebiomedicine|December 6, 2021
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2Thomas S Fulford, Huy Van, Nicholas A Gherardin, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Cell|July 26, 2016
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A VirusesM Gordon Joyce, Adam K Wheatley, Paul V Thomas, et al.
Ebiomedicine|May 6, 2023
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineGeorgia Deliyannis, Nicholas A Gherardin, Chinn Yi Wong, et al.
Pageof 30

Showing results (281-290 of 300) with videos related to

Sort By:
Pageof 30
Communications Medicine|May 23, 2022
A case report describing the immune response of an infant with congenital heart disease and severe COVID-19Danielle Wurzel, Melanie R Neeland, Jeremy Anderson, et al.
Nature Communications|November 12, 2020
Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19Shidan Tosif, Melanie R Neeland, Philip Sutton, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 24, 2021
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect micePhillip Pymm, Amy Adair, Li-Jin Chan, et al.
BMJ Open|October 29, 2021
BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial)Laure F Pittet, Nicole L Messina, Kaya Gardiner, et al.
NPJ Vaccines|October 6, 2025
Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccinationRuth A Purcell, Marios Koutsakos, Lukasz Kedzierski, et al.
Cell Reports|October 5, 2021
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domainAdam K Wheatley, Phillip Pymm, Robyn Esterbauer, et al.
Ebiomedicine|December 6, 2021
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2Thomas S Fulford, Huy Van, Nicholas A Gherardin, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Cell|July 26, 2016
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A VirusesM Gordon Joyce, Adam K Wheatley, Paul V Thomas, et al.
Ebiomedicine|May 6, 2023
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineGeorgia Deliyannis, Nicholas A Gherardin, Chinn Yi Wong, et al.
Pageof 30